Axsome Therapeutics (NASDAQ:AXSM) Receives Outperform Rating from William Blair

William Blair reiterated their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM - Free Report) in a research note published on Tuesday,RTT News reports. William Blair also issued estimates for Axsome Therapeutics' Q1 2025 earnings at ($1.46) EPS, Q2 2025 earnings at ($1.28) EPS, Q3 2025 earnings at ($0.92) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($4.23) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.93 EPS, Q4 2026 earnings at $1.62 EPS, FY2026 earnings at $2.38 EPS and FY2027 earnings at $13.85 EPS.

A number of other research analysts have also issued reports on the stock. Truist Financial boosted their price target on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Wells Fargo & Company boosted their price target on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. HC Wainwright reissued a "buy" rating and set a $190.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, February 11th. Leerink Partners boosted their price objective on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an "outperform" rating in a report on Monday, February 10th. Finally, Mizuho boosted their price objective on shares of Axsome Therapeutics from $137.00 to $195.00 and gave the stock an "outperform" rating in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Axsome Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $155.47.

Axsome Therapeutics Stock Performance

NASDAQ AXSM traded up $8.65 during trading on Tuesday, reaching $137.75. The company's stock had a trading volume of 1,539,053 shares, compared to its average volume of 1,102,240. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $139.13. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.37 and a current ratio of 2.11. The business's fifty day moving average price is $100.34 and its 200-day moving average price is $94.46. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of -23.00 and a beta of 1.05.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The business had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. As a group, analysts anticipate that Axsome Therapeutics will post -2.26 EPS for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the company's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares of the company's stock, valued at $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 22.40% of the company's stock.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors have recently modified their holdings of the company. Pitcairn Co. raised its position in shares of Axsome Therapeutics by 3.4% in the fourth quarter. Pitcairn Co. now owns 4,562 shares of the company's stock valued at $386,000 after buying an additional 148 shares during the last quarter. Meridian Wealth Management LLC raised its position in shares of Axsome Therapeutics by 0.7% in the fourth quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company's stock valued at $1,791,000 after buying an additional 150 shares during the last quarter. Summit Investment Advisors Inc. raised its position in shares of Axsome Therapeutics by 4.4% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,852 shares of the company's stock valued at $326,000 after buying an additional 162 shares during the last quarter. Arizona State Retirement System raised its position in shares of Axsome Therapeutics by 1.8% in the fourth quarter. Arizona State Retirement System now owns 9,054 shares of the company's stock valued at $766,000 after buying an additional 164 shares during the last quarter. Finally, Intrust Bank NA raised its position in shares of Axsome Therapeutics by 6.9% in the fourth quarter. Intrust Bank NA now owns 2,823 shares of the company's stock valued at $239,000 after buying an additional 183 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.